<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical features and diagnosis of narcolepsy in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical features and diagnosis of narcolepsy in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical features and diagnosis of narcolepsy in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kiran Maski, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Suresh Kotagal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas E Scammell, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronald D Chervin, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H90791744">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Narcolepsy is a chronic neurologic disorder characterized by excessive and irresistible sleepiness, cataplexy (episodes of muscle weakness during periods of strong emotion), hypnagogic hallucinations (vivid dreams at sleep onset), and sleep paralysis (a momentary inability to move the body as one is drifting off to sleep or upon waking up).
        </p>
        <p>
         Narcolepsy has two forms in both children and adults, depending on whether cataplexy is present [
         <a href="#rid1">
          1
         </a>
         ]. Narcolepsy type 1, previously called narcolepsy with cataplexy, includes cataplexy as one of the earliest symptoms and is associated with low cerebrospinal fluid (CSF) orexin (also called hypocretin) levels. Narcolepsy type 2, or narcolepsy without cataplexy, shares all of the features of narcolepsy type 1 except cataplexy and low CSF orexin.
        </p>
        <p>
         In children, narcolepsy is often overlooked as a cause of disabling sleepiness, and delays in the diagnosis are common. When narcolepsy starts in childhood, which it commonly can, it can have several unique features, including atypical cataplexy characterized by facial hypotonia or positive motor signs, precocious puberty, rapid unexplained weight gain, and daytime sleepiness manifesting primarily as habitual napping or irritability and hyperactivity.
        </p>
        <p>
         This topic will review the clinical features and diagnosis of narcolepsy in children. Management in children, and diagnosis and treatment of narcolepsy in adults, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/131001.html" rel="external">
          "Management and prognosis of narcolepsy in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7689.html" rel="external">
          "Clinical features and diagnosis of narcolepsy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7681.html" rel="external">
          "Treatment of narcolepsy in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31532813">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology of narcolepsy in children is not well characterized.
        </p>
        <p>
         A European study estimated a pooled incidence rate of 0.83 per 100,000 person-years in children aged 5 to 19 years [
         <a href="#rid2">
          2
         </a>
         ]. The overall prevalence of narcolepsy in Western countries has been estimated at 20 to 50 cases per 100,000 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         There are no studies that have examined the relative proportions of type 1 and type 2 narcolepsy in children.
        </p>
        <p class="headingAnchor" id="H3466443398">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the majority of cases, narcolepsy in children is sporadic and of unknown etiology. Genetic susceptibility and immune dysregulation likely play essential roles in narcolepsy type 1. (See
         <a class="local">
          'Pathophysiology'
         </a>
         below.)
        </p>
        <p>
         Secondary narcolepsy can occur due to structural lesions affecting the hypothalamus and/or brainstem, perhaps via disruption of orexin signaling. Narcolepsy can also occur with genetic syndromes and acquired disorders such as autoimmune encephalitis. (See
         <a class="local">
          'Pathophysiology'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H31532819">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Loss of orexin (also known as hypocretin) neurons
         </strong>
         – Clinicopathologic studies in narcolepsy type 1 show selective loss of orexin-secreting neurons in the hypothalamus and little or no detectable orexin in the cerebrospinal fluid. An increase in histaminergic neurons of the tuberomammillary region has also been observed in people with narcolepsy type 1, but the clinical significance is unclear [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7689.html" rel="external">
          "Clinical features and diagnosis of narcolepsy in adults", section on 'Orexin/hypocretin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many of the clinical manifestations of narcolepsy type 1 result from loss of the neurons producing the orexin neuropeptides. Orexins suppress rapid eye movement (REM) sleep, and orexin neuron loss results in REM sleep disinhibition. Many narcolepsy symptoms, including dream-like hallucinations before falling asleep or upon waking, sleep paralysis, and cataplexy, relate to intrusions of the dream-like imagery and muscle atonia experienced in REM sleep [
         <a href="#rid5">
          5,6
         </a>
         ]. Orexins also stabilize sleep and wake states; with orexin neuronal loss, people have trouble maintaining long periods of wake or sleep [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic and immune factors
         </strong>
         – Genetic factors likely play an important role in the predisposition for narcolepsy. There is a strong association between the DQB1*0602 human leukocyte antigen (HLA) haplotype and narcolepsy type 1. These and other factors are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7689.html" rel="external">
          "Clinical features and diagnosis of narcolepsy in adults", section on 'Genetic factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary narcolepsy
         </strong>
         – While narcolepsy is idiopathic in the majority of cases, structural lesions affecting the diencephalon and/or brainstem occasionally precipitate secondary narcolepsy, perhaps via disruption of orexin secretion [
         <a href="#rid8">
          8
         </a>
         ]. Hypothalamic glioma, craniopharyngioma, sarcoidosis, and head injury have all been associated with secondary narcolepsy in children [
         <a href="#rid9">
          9,10
         </a>
         ]. Case reports and series report narcolepsy development with anti-N-methyl-D-aspartate (NMDA) receptor antibody encephalitis [
         <a href="#rid11">
          11
         </a>
         ], multiple sclerosis, and neuromyelitis optica [
         <a href="#rid12">
          12
         </a>
         ]. Narcolepsy can also occur with genetic syndromes such as Prader-Willi syndrome [
         <a href="#rid13">
          13
         </a>
         ], Coffin-Lowry syndrome, Norrie disease [
         <a href="#rid8">
          8,14
         </a>
         ], myotonic dystrophy [
         <a href="#rid15">
          15
         </a>
         ], and Niemann-Pick disease type C [
         <a href="#rid14">
          14,16-18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Association with H1N1 influenza A
         </strong>
         – The incidence of narcolepsy abruptly increased in the midst of the 2009 H1N1 influenza A pandemic, with most new cases in children and adolescents. The annual incidence increased about fourfold in China, which had low levels of vaccination against influenza [
         <a href="#rid19">
          19
         </a>
         ], and 1.6-fold in the United States [
         <a href="#rid20">
          20
         </a>
         ]. In northern Europe, vaccination with Pandemrix, an AS03-adjuvanted influenza vaccine, was associated with a 5- to 14-fold increase in incidence of narcolepsy in children and adolescents [
         <a href="#rid21">
          21
         </a>
         ]. In studies that included HLA testing, all affected children were HLA DQB1*0602 haplotype positive [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Molecular mimicry and autoimmunity are likely implicated, related to an antigen in the Pandemrix vaccine, the influenza infection itself [
         <a href="#rid23">
          23-26
         </a>
         ], or to both [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7689.html" rel="external">
          "Clinical features and diagnosis of narcolepsy in adults", section on 'Autoimmune hypothesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31532825">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive daytime sleepiness (EDS) is an essential clinical feature of narcolepsy and is the most common presenting symptom in both children and adults.
        </p>
        <p>
         The classic tetrad of narcolepsy type 1 symptoms is EDS, cataplexy, hypnagogic hallucinations, and sleep paralysis. However, only 10 to 25 percent of people with narcolepsy type 1 have this complete tetrad of symptoms [
         <a href="#rid29">
          29,30
         </a>
         ], making diagnosis challenging. Sleep paralysis and other symptoms may gradually appear over time. Overall, survey data have shown that clinicians are unfamiliar with narcolepsy symptoms [
         <a href="#rid31">
          31
         </a>
         ], and this lack of awareness likely contributes to delays in diagnosis [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2354600040">
         <span class="h2">
          Age of onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         Narcolepsy is a lifelong disorder that most commonly begins in the first, second, or early third decade of life. Approximately one-third of patients develop symptoms before 15 years of age, and up to 5 percent of cases begin before the age of five years [
         <a href="#rid33">
          33
         </a>
         ]. Anecdotally, the age of onset of narcolepsy type 2 may be slightly later than narcolepsy type 1.
        </p>
        <p class="headingAnchor" id="H182340970">
         <span class="h2">
          Daytime sleepiness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Daytime sleepiness is present in all children with narcolepsy and is usually the first symptom. The onset can be as early as five to six years of age, but in rare cases it may be apparent even in the preschool years.
        </p>
        <p>
         The severity of daytime sleepiness ranges from waxing and waning drowsiness to irresistible, unintended lapses into sleep (often referred to as sleep attacks). Lapses into sleep can occur throughout the day but are most likely to occur during sedentary activities such as sitting in a classroom, reading a book, or being driven in a car. People with narcolepsy typically report that short naps (10 to 20 minutes) are refreshing.
        </p>
        <p>
         Daytime sleepiness sometimes manifests as habitual napping that occurs after a child typically grows out of the need for daily naps. Specifically, habitual napping is uncommon in healthy children after five to six years of age, and when present, it should raise suspicion for pathologic sleepiness.
        </p>
        <p>
         When sleepiness is mild or subtle, caregivers may instead report a history of irritability, poor concentration, or memory impairment, especially in younger children [
         <a href="#rid34">
          34
         </a>
         ]. Children with daytime sleepiness can be mistaken for being "lazy" and may become the target of negative comments from their peers. These behavioral manifestations of sleepiness may also be perceived to be symptoms of attention deficit hyperactivity disorder (ADHD), although ADHD may also be a comorbidity of narcolepsy [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Daytime sleepiness in narcolepsy may be associated with automatic behaviors of which the child is unaware. This can manifest as a segment of sloppy handwriting in an assignment or performing routine tasks with little recollection of them afterwards.
        </p>
        <p>
         The Pediatric Daytime Sleepiness Scale (PDSS) has been validated in children ages 11 to 15 years old and can be used to quantify subjective daytime sleepiness  (
         <a class="graphic graphic_table graphicRef104093" href="/z/d/graphic/104093.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid36">
          36
         </a>
         ]. Total PDSS scores range from 0 to 32, with higher scores indicative of more severe sleepiness. The median PDSS score in healthy teenagers is 16 [
         <a href="#rid36">
          36
         </a>
         ]. In a cohort of 31 children with newly diagnosed narcolepsy (mean age 13 years), the mean PDSS score was 22 [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         A version of the Epworth Sleepiness Scale (ESS) that has been modified for children and adolescents (ESS-CHAD)  (
         <a class="graphic graphic_form graphicRef131990" href="/z/d/graphic/131990.html" rel="external">
          form 1
         </a>
         ) is also used by some clinicians, with elevated scores indicating sleepiness [
         <a href="#rid38">
          38
         </a>
         ]. The ESS-CHAD shows good validity and reliability for children 7 to 18 years [
         <a href="#rid39">
          39,40
         </a>
         ]. Based on clinical experience, untreated pediatric narcolepsy patients typically have an ESS-CHAD score greater than 15, although reference values have not been firmly established in teenagers.
        </p>
        <p class="headingAnchor" id="H31532831">
         <span class="h2">
          Cataplexy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cataplexy is the most specific symptom of narcolepsy. It is seen in approximately 80 percent of children with narcolepsy [
         <a href="#rid33">
          33
         </a>
         ]. It typically emerges around the same time as excessive sleepiness or in the months thereafter.
        </p>
        <p>
         Typical cataplexy is characterized by sudden, transient, and symmetric loss of muscle tone; the weakness or paralysis usually arises in response to strong emotions such as laughter, surprise, anger, fright, or anticipation of reward. Consciousness is fully preserved. Episodes usually last &lt;1 minute with full return of function thereafter. Cataplexy attacks rarely last &gt;2 minutes, but if a particular trigger continues, consecutive attacks can merge to form what seems to be one long episode. The severity of attacks ranges from a slight head or shoulder drop (partial cataplexy) to buckling of the knees and sudden collapse to the floor (full cataplexy).
        </p>
        <p>
         By contrast, the following characteristics are atypical for cataplexy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attacks never triggered by laughing, mirth, or joking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged attacks in adults (eg, &gt;3 minutes) in the absence of an ongoing precipitant
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of clear triggers of the episodes or negative emotions (such as anxiety, fear, or a sudden, startling noise) as the sole triggers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Purely unilateral attacks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperacute generalized muscle weakness without build-up over seconds, leading to falls and injuries
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged recovery time (several minutes) needed to recover after a single attack
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncertainty regarding the preservation of consciousness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusively generalized attacks without a history of partial episodes
        </p>
        <p>
        </p>
        <p>
         If two or more of these characteristics are present, the episodes should not be labeled as typical cataplexy. Patients with narcolepsy type 1 may report both typical and atypical cataplexy events. If only atypical cataplexy is reported, the patient should not be diagnosed at narcolepsy type 1 without cerebrospinal fluid (CSF) orexin testing confirmation. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
         Young children often present with atypical positive or negative motor features, which later evolve into more typical cataplexy [
         <a href="#rid41">
          41
         </a>
         ]. Persistent cataplexy characterized by facial weakness is common in children, manifested by the jaw dropping open, eyelid drooping (ptosis), head rolling, or tongue thrusting movements [
         <a href="#rid42">
          42
         </a>
         ]. This has given rise to the term "cataplectic facies," which is a unique clinical feature of childhood narcolepsy [
         <a href="#rid42">
          42,43
         </a>
         ]. This weakness is likely sustained, partial cataplexy that is not triggered by emotion. Other manifestations of atypical cataplexy in children may include positive motor signs such as eyebrow raising, perioral movements, and head/trunk swaying [
         <a href="#rid41">
          41
         </a>
         ]. Over the first years, these signs evolve into the classic form of brief cataplexy triggered by emotions [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         The frequency of cataplexy is variable. Children can have dozens of cataplexy episodes in a day, producing a clumsy and uncoordinated appearance. When in doubt as to the nature of these episodes, a review of videos provided by caregivers can be very helpful.
        </p>
        <p class="headingAnchor" id="H182340976">
         <span class="h2">
          Hypnagogic hallucinations and sleep paralysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypnagogic hallucinations and sleep paralysis are seen in approximately 50 to 60 percent of children with narcolepsy. Like cataplexy, these phenomena may represent episodic intrusion of fragments of rapid eye movement (REM) sleep onto wakefulness.
        </p>
        <p>
         Hypnagogic hallucinations consist of vivid, dream-like imagery at sleep onset; the same phenomena can more occasionally occur on awakening, when they are then referred to as hypnopompic hallucinations. Sleep paralysis is a momentary inability to move the body, most commonly on awakening in the morning or during the night, but occasionally as one is drifting off to sleep.
        </p>
        <p>
         Children below the age of five to six years are usually unable to provide a reliable history for hypnagogic hallucinations and sleep paralysis. Children may find the experiences frightening, such that symptoms are initially attributed to nightmares, sleep terrors, or other parasomnias. (See
         <a class="medical medical_review" href="/z/d/html/16588.html" rel="external">
          "Parasomnias of childhood, including sleepwalking", section on 'Sleep terrors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2449421128">
         <span class="h2">
          Other common features
         </span>
        </p>
        <p class="headingAnchor" id="H2546397283">
         <span class="h3">
          Awakenings and movements during sleep
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disrupted nighttime sleep is a core symptom of narcolepsy in both children and adults [
         <a href="#rid44">
          44
         </a>
         ]. Children with narcolepsy often have frequent, brief awakenings, which may or may not be associated with periodic leg movements. (See
         <a class="medical medical_review" href="/z/d/html/7689.html" rel="external">
          "Clinical features and diagnosis of narcolepsy in adults", section on 'Other features'
         </a>
         .)
        </p>
        <p>
         In addition to awakenings, complex motor behaviors may arise during REM sleep due to incomplete muscle paralysis [
         <a href="#rid45">
          45,46
         </a>
         ]. In a series of 40 children with type 1 narcolepsy who underwent video polysomnography (PSG), 32 percent of patients exhibited complex motor behaviors during REM sleep consistent with REM sleep behavior disorder (RBD), compared with none of 22 age- and sex-matched controls [
         <a href="#rid47">
          47
         </a>
         ]. Movements included both vigorous dream enactment motions (eg, vivid gestures, throwing something, raising the head and reaching or grabbing) and pantomime-like events characterized by slow, calm, and repetitive gesturing. Events were more common among children with impaired nighttime sleep, worse daytime sleepiness, and cataplectic facies/status cataplecticus.
        </p>
        <p class="headingAnchor" id="H261010357">
         <span class="h3">
          Neuropsychiatric symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depression is common in both children and adults with narcolepsy [
         <a href="#rid48">
          48
         </a>
         ]. Children are also at risk for aggressive behavior, symptoms of ADHD, social and emotional distress, and decreased school performance and engagement [
         <a href="#rid49">
          49-52
         </a>
         ]. Cognitive deficits have also been reported [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H182340989">
         <span class="h3">
          Obesity and precocious puberty
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the unique features of childhood narcolepsy type 1 is its association with obesity, which is often present at the onset of daytime sleepiness [
         <a href="#rid54">
          54,55
         </a>
         ]. The mechanism of weight gain, which is often sudden, is not yet clear; decreased energy expenditure as well as a decrease in basal metabolic rate have each been observed [
         <a href="#rid55">
          55,56
         </a>
         ].
        </p>
        <p>
         Within a few years of diagnosis, approximately two-thirds of children with narcolepsy are overweight or obese [
         <a href="#rid41">
          41,55,57
         </a>
         ]. The age of onset of narcolepsy symptoms seems to be earlier in children with obesity compared with those who are not obese [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Precocious puberty also occurs with increased frequency in children with narcolepsy, affecting 17 percent of children with narcolepsy compared with 2 percent of similarly aged control children with obesity [
         <a href="#rid58">
          58
         </a>
         ]. In one study, all children with narcolepsy type 1 and precocious puberty were obese, but their body mass index (BMI) was not significantly higher than those with narcolepsy type 1 without precocious puberty [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31532837">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Narcolepsy is a rare cause of excessive daytime sleepiness (EDS) in children; however, the more severe the sleepiness, the more important it is to consider narcolepsy as a potential cause.
        </p>
        <p class="headingAnchor" id="H985974742">
         <span class="h2">
          Other causes of sleepiness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Particularly when there is no history of cataplexy, alternative and more common causes of EDS should be considered, including insufficient sleep due to poor sleep hygiene and fragmented sleep due to disorders such as obstructive sleep apnea  (
         <a class="graphic graphic_table graphicRef104798" href="/z/d/graphic/104798.html" rel="external">
          table 2
         </a>
         ). Other causes of sleepiness to consider are medication side effects, substance abuse, delayed sleep-wake phase disorder (in teenagers), depression, and underlying medical conditions. (See
         <a class="medical medical_review" href="/z/d/html/6357.html" rel="external">
          "Assessment of sleep disorders in children", section on 'Excessive daytime sleepiness'
         </a>
         .)
        </p>
        <p>
         Most of these causes of EDS can be differentiated from narcolepsy by history and the absence of additional clinical features of narcolepsy (ie, cataplexy, sleep attacks, hypnagogic hallucinations, and sleep paralysis). Notably, however, hypnagogic hallucinations, sleep paralysis, and sleep attacks are not specific to narcolepsy and can occur as isolated phenomena, precipitated by insufficient or fragmented sleep. Wrist actigraphy and sleep logs maintained for two to three weeks can help exclude insufficient sleep and delayed sleep phase syndrome.
        </p>
        <p>
         Children with obstructive sleep apnea usually have snoring or other indications on history of abnormal breathing during sleep, and polysomnography (PSG) is needed to confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/6363.html" rel="external">
          "Evaluation of suspected obstructive sleep apnea in children", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H726108399">
         <span class="h2">
          Mimics of cataplexy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cataplexy in children is sometimes confused with atonic seizures. Unlike cataplexy, however, seizures are not typically triggered by strong emotions, and seizures that cause falls usually include loss of consciousness and are followed by confusion and obtundation. Cataplexy also can be confused with syncope. Unlike cataplexy, syncope is preceded by vision and/or hearing changes and lightheadedness and is associated with loss of consciousness.
        </p>
        <p>
         With persistent cataplexy (cataplectic facies), ptosis and a slack jaw are common, mimicking myasthenias gravis (MG). However, unlike in MG, a history of excessive sleepiness is almost always present before, or concurrent with facial symptoms. (See
         <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">
          "Clinical manifestations of myasthenia gravis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3370625074">
         <span class="h2">
          Other central disorders of hypersomnolence
         </span>
         <span class="headingEndMark">
          —
         </span>
         More rare central disorders of hypersomnolence can cause severe daytime sleepiness beginning in childhood, including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Idiopathic hypersomnia
         </strong>
         – Patients with idiopathic hypersomnia do not have cataplexy, but on rare occasions they may exhibit features such as hypnagogic hallucinations, sleep paralysis, or sleep attacks. They often have increased amounts of sleep over a 24-hour period. Idiopathic hypersomnia is typically considered only after other causes of sleepiness have been ruled out by both history and PSG. PSG followed by a multiple sleep latency test (MSLT) is required for the diagnosis of idiopathic hypersomnia. These tests show characteristic findings that are distinct from narcolepsy (ie, a shortened mean sleep latency but fewer than two sleep-onset REM periods [SOREMPs]). (See
         <a class="medical medical_review" href="/z/d/html/14890.html" rel="external">
          "Idiopathic hypersomnia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kleine-Levin syndrome (KLS)
         </strong>
         – KLS is unique for its episodic course of hypersomnia lasting days to weeks followed by periods of normal daytime alertness and sleep. During these episodes of hypersomnia, patients commonly have cognitive disturbances, anorexia or hyperphagia, memory impairment, derealization, and severe apathy. They may also exhibit disinhibition in the form of hypersexuality. The strikingly episodic nature of EDS in KLS and the prominent cognitive and behavioral disturbances distinguish it from narcolepsy, which manifests with daily, nonremitting symptoms. (See
         <a class="medical medical_review" href="/z/d/html/14897.html" rel="external">
          "Kleine-Levin syndrome (recurrent hypersomnia)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid-onset Obesity, Hypoventilation, Hypothalamic and Autonomic Dysfunction (ROHHAD)
         </strong>
         – ROHHAD is a rare cause of acquired sleepiness in children [
         <a href="#rid59">
          59
         </a>
         ]. It generally begins in the first decade and shows a slight female predominance. There is abrupt onset of obesity and sleep-related hypoventilation. Other common signs include altered thermoregulation, hyponatremia or hypernatremia, hyperprolactinemia, and neurobehavioral disturbances. No specific etiology has been found, and the condition is progressive. Noninvasive ventilation or tracheostomy combined with a home ventilator may be required. (See
         <a class="medical medical_review" href="/z/d/html/97858.html" rel="external">
          "Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children", section on 'Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3316431842">
         <span class="h1">
          EVALUATION AND REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Narcolepsy should be suspected in children presenting with the subacute onset of severe daytime sleepiness leading to sleep attacks and daytime naps, particularly when there is also a history of cataplexy, sleep paralysis, or new obesity. Cataplexy in young children can be subtle with mainly persistent facial weakness. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         The initial evaluation consists of a history directed at identifying potential causes of sleepiness and recognizing other characteristic features of narcolepsy that may be overlooked by the child and caregivers. The sleep history should be structured, systematic, and detailed. An approach to the initial evaluation is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6357.html" rel="external">
          "Assessment of sleep disorders in children", section on 'Excessive daytime sleepiness'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6357.html" rel="external">
          "Assessment of sleep disorders in children"
         </a>
         .)
        </p>
        <p>
         Children with suspected narcolepsy should be referred to a sleep medicine clinician with pediatric training or experience for evaluation prior to formal diagnostic sleep testing. The diagnosis of narcolepsy rests heavily on polysomnography (PSG) and a multiple sleep latency test (MSLT), which require an overnight stay in a sleep laboratory and meticulous planning to avoid confounding effects of sleep insufficiency and medications. Lumbar puncture for measurement of cerebrospinal fluid (CSF) orexin levels should be considered in some patients. (See
         <a class="local">
          'CSF orexin (hypocretin-1) testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2725313316">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of narcolepsy is established on the basis of characteristic clinical features combined with nocturnal polysomnography (PSG) and a multiple sleep latency test (MSLT).
        </p>
        <p class="headingAnchor" id="H376541822">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic criteria for narcolepsy are identical for children and adults [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         A diagnosis of
         <strong>
          narcolepsy type 1
         </strong>
         requires all of the following  (
         <a class="graphic graphic_table graphicRef103709" href="/z/d/graphic/103709.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daily periods of irrepressible need to sleep or daytime lapses into sleep. In young children, narcolepsy sometimes presents as excessively long night of sleep or resumption of previously discontinued daytime napping.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of one or both of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cataplexy and either:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mean sleep latency of ≤8 minutes and two or more sleep-onset rapid eye movement periods (SOREMPs) on an MSLT performed according to standard techniques.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A SOREMP (within 15 minutes of sleep onset) on nocturnal PSG.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebrospinal fluid (CSF) orexin (hypocretin-1) concentration is ≤110 picograms/mL (or less than one-third of mean values obtained in normal subjects) with a standardized radioimmunoassay.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The symptoms and signs are not better explained by chronic insufficient sleep, a circadian rhythm sleep-wake disorder or other current sleep disorder, mental disorder, or medication/substance use or withdrawal
         <strong>
          .
         </strong>
        </p>
        <p>
        </p>
        <p>
         If a patient lacks cataplexy or if the CSF orexin level is &gt;110 picograms/mL,
         <strong>
          narcolepsy type 2
         </strong>
         is diagnosed, assuming other criteria are met  (
         <a class="graphic graphic_table graphicRef103711" href="/z/d/graphic/103711.html" rel="external">
          table 4
         </a>
         ). If cataplexy emerges later, the disorder is reclassified as narcolepsy type 1. The validity of a SOREMP on the nocturnal PSG for diagnosis of narcolepsy type 2 is unknown.
        </p>
        <p class="headingAnchor" id="H4189767235">
         <span class="h2">
          Sleep studies
         </span>
        </p>
        <p class="headingAnchor" id="H376541786">
         <span class="h3">
          Polysomnography
         </span>
         <span class="headingEndMark">
          —
         </span>
         All children with suspected narcolepsy require nocturnal PSG, and most children also require MSLT the following day.
        </p>
        <p>
         The main purpose of PSG in the diagnostic evaluation of narcolepsy is to exclude alternative or coexisting causes of chronic daytime sleepiness, and to ensure that an adequate amount of sleep has been obtained before the MSLT. However, based on updated diagnostic criteria reflected in the International Classification of Sleep Disorders, third edition, text revision (ICSD-3-TR), the nocturnal PSG should also be scrutinized for the presence of a SOREMP within 15 minutes of sleep onset [
         <a href="#rid1">
          1
         </a>
         ]. This is a highly specific finding associated with narcolepsy type 1 in adults and children [
         <a href="#rid60">
          60
         </a>
         ]. Its presence is now sufficient to diagnose narcolepsy type 1 in the setting of typical symptoms of narcolepsy with cataplexy.
        </p>
        <p>
         In some cases, patients have had a prior PSG to rule out sleep-disordered breathing, with normal results or mild OSA thought not severe enough to account for the presence of severe daytime sleepiness. Such testing should be reviewed for the presence of a nocturnal SOREMP. If found and the patient has severe daytime sleepiness and cataplexy, further diagnostic testing may be unnecessary.
        </p>
        <p>
         In addition to scrutiny for a SOREMP within 15 minutes of sleep onset, we also review the nocturnal PSG for other markers of narcolepsy type 1, including rapid eye movement (REM) sleep without atonia, objective measures of disrupted nighttime sleep (eg, wake/N1 index [number of transitions from sleep to wake or N1 sleep per hour of sleep time]), and frequent transitions from REM sleep to wake or N1 [
         <a href="#rid44">
          44,61-63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H799965448">
         <span class="h3">
          Multiple sleep latency test
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic PSG and MSLT require meticulous preparation to avoid confounding effects of sleep insufficiency and medications [
         <a href="#rid64">
          64-66
         </a>
         ]. Children, including teenagers, need more sleep than adults, so the amount of sleep on the PSG the night before the MSLT should meet age-based needs [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications that can impact sleep-wake function (eg, stimulants, antidepressants) should be stopped for at least two weeks prior to the study, provided it is safe to do so. Longer washout of medications may be needed for drugs with a very long half-life (eg,
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         ) [
         <a href="#rid68">
          68
         </a>
         ]. This may require input and advice from the patient's primary care physician and/or child psychiatrist. Stimulants and antidepressants suppress REM sleep and can prevent the appearance of SOREMPs; conversely, abrupt discontinuation can result in REM rebound effects that include the appearance of SOREMPs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine drug screen for drugs of abuse is routinely performed during the MSLT test and commonly includes screening of substances such as amphetamines and marijuana [
         <a href="#rid69">
          69
         </a>
         ]. In one study, caffeine was the most commonly reported positive result in a pediatric sleep laboratory conducting PSG-MSLT testing [
         <a href="#rid70">
          70
         </a>
         ]. Clinicians are advised to ask about sedating/alerting substances including caffeine use when ordering PSG-MSLT testing and provide instructions about discontinuation based on their half-lives.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep logs and ideally wrist actigraphy should be obtained for at least two weeks before the MSLT [
         <a href="#rid66">
          66
         </a>
         ], as insufficient sleep or circadian rhythm disturbances (most commonly delayed sleep phase syndrome) can produce false positive MSLT results specifically for narcolepsy type 2 [
         <a href="#rid71">
          71
         </a>
         ]. Actigraphy reliably estimates total time in bed, total sleep time, and sleep efficiency. (See
         <a class="medical medical_review" href="/z/d/html/107759.html" rel="external">
          "Actigraphy in the evaluation of sleep disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The MSLT is started the morning after the PSG and consists of five 20-minute nap opportunities at two-hour intervals across the day. The latency until sleep onset is measured for each nap opportunity, and multichannel sleep recordings are analyzed to detect sleep stage transitions and the presence or absence of REM sleep during each nap. (See
         <a class="medical medical_review" href="/z/d/html/6357.html" rel="external">
          "Assessment of sleep disorders in children", section on 'Multiple sleep latency test'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1186481468">
         <span class="h3">
          Diagnostic accuracy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a nocturnal PSG alone is conducted, the presence of a nocturnal SOREMP (REM sleep onset latency of ≤15 minutes) is highly specific for pediatric narcolepsy type 1 (97 percent) but has low sensitivity (55 percent) [
         <a href="#rid60">
          60
         </a>
         ]. A child with a mean sleep latency &gt;8 minutes may still have excessive daytime sleepiness, but age-specific criteria for diagnosis of narcolepsy have not yet been established.
        </p>
        <p>
         The MSLT diagnostic criteria for narcolepsy are currently the same in children as they are in adults, despite the fact that normal mean sleep latency for children is likely considerably higher than for adults [
         <a href="#rid72">
          72
         </a>
         ]. Pediatric-specific MSLT protocol recommendations are in development by the American Academy of Sleep Medicine.
        </p>
        <p>
         In children as young as three years of age, a validation study identified alternative cutoffs for narcolepsy type 1 diagnosis. The study authors found that either ≥2 SOREMPs
         <strong>
          or
         </strong>
         a mean sleep latency ≤8.2 minutes had high sensitivity and specificity for the diagnosis of narcolepsy type 1 (against a gold standard of CSF orexin &lt;110 pg/mL) [
         <a href="#rid73">
          73
         </a>
         ]. A combination of the two measures did not improve diagnostic accuracy. On the other hand, when both of these measures were negative, narcolepsy type 1 could be ruled out in 99.5 percent of cases. The study did not address test performance for narcolepsy type 2. Further research to assess results compared with other sleep disorders such as obstructive sleep apnea and to explore generalizability of these findings is needed.
        </p>
        <p>
         The diagnosis of narcolepsy in young children can be difficult and sometimes requires delaying testing until a child is at least six years of age or obtaining CSF orexin to make a definitive diagnosis.
        </p>
        <p class="headingAnchor" id="H376541792">
         <span class="h2">
          CSF orexin (hypocretin-1) testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         A low cerebrospinal fluid (CSF) orexin level (&lt;110 pg/mL) is highly sensitive and specific for a diagnosis of narcolepsy type 1, and a commercially available assay for CSF orexin is available in the United States through Mayo Clinic Laboratories.
        </p>
        <p>
         Measurement of orexin is most useful when the diagnosis of narcolepsy type 1 is equivocal [
         <a href="#rid74">
          74
         </a>
         ]. Examples include a child below the age of five years, in whom the MSLT is not validated, and instances in which the patient is already on an antidepressant medication, which cannot be safely stopped for diagnostic sleep tests. Up to 95 percent of patients with narcolepsy with cataplexy and orexin deficiency are also positive for the human leukocyte antigen (HLA) DQB1*0602 [
         <a href="#rid75">
          75,76
         </a>
         ], so testing for presence of this haplotype is recommended before proceeding to lumbar puncture for the orexin assay.
        </p>
        <p class="headingAnchor" id="H376541798">
         <span class="h2">
          Other tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuroimaging in patients with narcolepsy is typically normal but may be indicated to rule out alternative causes of excessive sleepiness, particularly in the presence of focal neurologic findings or a history suggestive of increased intracranial pressure.
        </p>
        <p>
         Although the HLA DQB1*0602 haplotype is present in the majority of individuals with narcolepsy type 1 (85 to 95 percent) [
         <a href="#rid77">
          77
         </a>
         ], it is not sufficiently specific to be useful as a routine diagnostic test. However, given high prevalence among people with narcolepsy type 1, it is helpful as a screening test for narcolepsy type 1 in patients with atypical events suggestive of possible cataplexy.
        </p>
        <p class="headingAnchor" id="H1408043306">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113024.html" rel="external">
          "Society guideline links: Parasomnias, hypersomnias, and circadian rhythm disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2299410915">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83679.html" rel="external">
          "Patient education: Narcolepsy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H90791778">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – Narcolepsy in children is mostly sporadic and, for narcolepsy type 1, caused by loss of orexin neurons in the hypothalamus. Rare cases of secondary narcolepsy are usually due to structural lesions in the hypothalamus or brainstem. The cause of narcolepsy type 2 is unknown. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Genetic susceptibility and immune dysregulation likely play a central role in narcolepsy type 1, resulting in selective loss of orexin-secreting neurons in the hypothalamus. Orexin deficiency in turn causes sleep-state instability and inappropriate intrusions of rapid eye movement (REM) sleep into wakefulness. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age of onset
         </strong>
         – In about one-third of patients, narcolepsy symptoms begin before the age of 15 years. Narcolepsy can present in children as young as six years of age, rarely even younger. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Excessive daytime sleepiness (EDS)
         </strong>
         – All children with narcolepsy have EDS. The severity ranges from waxing and waning drowsiness to irresistible, unintended, frequent lapses into sleep (sleep attacks). When sleepiness is mild or subtle, caregivers may instead report a history of irritability, poor concentration, or memory impairment. (See
         <a class="local">
          'Daytime sleepiness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cataplexy
         </strong>
         – Cataplexy involves sudden, transient loss of muscle tone, usually in response to strong emotions. In young children, cataplexy often involves the buccofacial muscles, with jaw opening, eyelid drooping (ptosis), head rolling, or tongue thrusting movements early in the disease course. (See
         <a class="local">
          'Cataplexy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other key features
         </strong>
         – Additional core features of narcolepsy seen in adults, such as hypnagogic hallucinations and sleep paralysis, may be absent or difficult to elicit in young children. (See
         <a class="local">
          'Hypnagogic hallucinations and sleep paralysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obesity
         </strong>
         – Obesity is common in children with narcolepsy and tends to happen suddenly, near the onset of other symptoms. (See
         <a class="local">
          'Obesity and precocious puberty'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of narcolepsy in children includes insufficient or fragmented sleep due to poor sleep hygiene, obstructive sleep apnea, medication side effects, depression, and underlying medical conditions, among many others  (
         <a class="graphic graphic_table graphicRef104798" href="/z/d/graphic/104798.html" rel="external">
          table 2
         </a>
         ). Mimics of cataplexy in children, such as atonic seizures, are important to recognize. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and referral
         </strong>
         – The initial evaluation consists of a history to identify potential causes of sleepiness and recognize other characteristic features of narcolepsy that may be subtle or overlooked by the child and caregivers. Children with suspected narcolepsy should be referred to a sleep medicine clinician with pediatric training or experience for evaluation prior to formal diagnostic sleep testing. (See
         <a class="local">
          'Evaluation and referral'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Narcolepsy is diagnosed by clinical features and supported by a nocturnal polysomnography (PSG) plus a multiple sleep latency test (MSLT). In the proper clinical context, two or more sleep-onset REM periods (SOREMPs) and a mean sleep latency of ≤8 minutes on MSLT are diagnostic of narcolepsy  (
         <a class="graphic graphic_table graphicRef103709" href="/z/d/graphic/103709.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef103711" href="/z/d/graphic/103711.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cerebrospinal fluid (CSF) orexin testing is an option in selected children who are human leukocyte antigen (HLA) DQB1*0602 positive and cannot comply with PSG-MSLT testing. (See
         <a class="local">
          'Polysomnography'
         </a>
         above and
         <a class="local">
          'CSF orexin (hypocretin-1) testing'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep 2007; 30:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valko PO, Gavrilov YV, Yamamoto M, et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 2013; 74:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci 2019; 20:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madan R, Pitts J, Patterson MC, et al. Secondary Narcolepsy in Children. J Child Neurol 2021; 36:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Autret A, Lucas B, Henry-Lebras F, de Toffol B. Symptomatic narcolepsies. Sleep 1994; 17:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weil AG, Muir K, Hukin J, et al. Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. Pediatr Neurol 2018; 84:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsutsui K, Kanbayashi T, Tanaka K, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012; 12:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009; 66:1563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cataldi M, Arnaldi D, Tucci V, et al. Sleep disorders in Prader-Willi syndrome, evidence from animal models and humans. Sleep Med Rev 2021; 57:101432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vossler DG, Wyler AR, Wilkus RJ, et al. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology 1996; 46:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Rodríguez JE, Lin L, Iranzo A, et al. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003; 26:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vankova J, Stepanova I, Jech R, et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 2003; 26:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandt RS, Emerson RG, Singer HS, et al. Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol 1982; 12:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manni R, Politini L, Nobili L, et al. Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors. Clin Neurophysiol 2001; 112:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Xiao F, Wang Y, et al. Changed epidemiology of narcolepsy before, during, and after the 2009 H1N1 pandemic: a nationwide narcolepsy surveillance network study in mainland China, 1990-2017. Sleep 2023; 46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simakajornboon N, Mignot E, Maski K, et al. Increased incidence of pediatric narcolepsy following the 2009 H1N1 pandemic: a report from the pediatric working group of the sleep research network. Sleep 2022; 45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granath F, Gedeborg R, Smedje H, Feltelius N. Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic. Pharmacoepidemiol Drug Saf 2019; 28:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szakács A, Darin N, Hallböök T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013; 80:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montplaisir J, Petit D, Quinn MJ, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One 2014; 9:e108489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feltelius N, Persson I, Ahlqvist-Rastad J, et al. A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden. J Intern Med 2015; 278:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturkenboom MC. The narcolepsy-pandemic influenza story: can the truth ever be unraveled? Vaccine 2015; 33 Suppl 2:B6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015; 7:294ra105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo G, Ambati A, Lin L, et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci U S A 2018; 115:E12323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim LJ, Coelho FM, Hirotsu C, et al. Frequencies and Associations of Narcolepsy-Related Symptoms: A Cross-Sectional Study. J Clin Sleep Med 2015; 11:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol 1990; 7:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter LP, Acebo C, Kim A. Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review. Postgrad Med 2014; 126:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maski K, Steinhart E, Williams D, et al. Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy. J Clin Sleep Med 2017; 13:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Challamel MJ, Mazzola ME, Nevsimalova S, et al. Narcolepsy in children. Sleep 1994; 17S:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babiker MO, Prasad M. Narcolepsy in children: a diagnostic and management approach. Pediatr Neurol 2015; 52:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lecendreux M, Lavault S, Lopez R, et al. Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study. Sleep 2015; 38:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drake C, Nickel C, Burduvali E, et al. The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep 2003; 26:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang CM, Huang YS, Song YC. Clinical utility of the Chinese version of the Pediatric Daytime Sleepiness Scale in children with obstructive sleep apnea syndrome and narcolepsy. Psychiatry Clin Neurosci 2010; 64:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee J, Na G, Joo EY, et al. Clinical and polysomnographic characteristics of excessive daytime sleepiness in children. Sleep Breath 2017; 21:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen KC, Phillipson S, O'Connor J, Johns MW. Validation of the Epworth Sleepiness Scale for Children and Adolescents using Rasch analysis. Sleep Med 2017; 33:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YG, Menno D, Chen A, et al. Validation of the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years. Sleep Med 2022; 89:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizza F, Franceschini C, Peltola H, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 2013; 136:3787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serra L, Montagna P, Mignot E, et al. Cataplexy features in childhood narcolepsy. Mov Disord 2008; 23:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad M, Setty G, Ponnusamy A, et al. Cataplectic facies: clinical marker in the diagnosis of childhood narcolepsy-report of two cases. Pediatr Neurol 2014; 50:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maski K, Pizza F, Liu S, et al. Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1. Sleep 2020; 43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nevsimalova S, Prihodova I, Kemlink D, et al. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med 2007; 8:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd R, Tippmann-Peikert M, Slocumb N, Kotagal S. Characteristics of REM sleep behavior disorder in childhood. J Clin Sleep Med 2012; 8:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antelmi E, Pizza F, Vandi S, et al. The spectrum of REM sleep-related episodes in children with type 1 narcolepsy. Brain 2017; 140:1669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stores G, Montgomery P, Wiggs L. The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics 2006; 118:e1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avis KT, Shen J, Weaver P, Schwebel DC. Psychosocial Characteristics of Children with Central Disorders of Hypersomnolence Versus Matched Healthy Children. J Clin Sleep Med 2015; 11:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quaedackers L, van Gilst MM, van Mierlo P, et al. Impaired social functioning in children with narcolepsy. Sleep 2019; 42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim J, Lee GH, Sung SM, et al. Prevalence of attention deficit hyperactivity disorder symptoms in narcolepsy: a systematic review. Sleep Med 2020; 65:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plazzi G, Clawges HM, Owens JA. Clinical Characteristics and Burden of Illness in Pediatric Patients with Narcolepsy. Pediatr Neurol 2018; 85:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szakács A, Hallböök T, Tideman P, et al. Psychiatric comorbidity and cognitive profile in children with narcolepsy with or without association to the H1N1 influenza vaccination. Sleep 2015; 38:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 2004; 5:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Wu H, Stone WS, et al. Body weight and basal metabolic rate in childhood narcolepsy: a longitudinal study. Sleep Med 2016; 25:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponziani V, Gennari M, Pizza F, et al. Growing Up with Type 1 Narcolepsy: Its Anthropometric and Endocrine Features. J Clin Sleep Med 2016; 12:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poli F, Pizza F, Mignot E, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep 2013; 36:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JM, Shin J, Kim S, et al. Rapid-Onset Obesity with Hypoventilation, Hypothalamic, Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET) Syndrome: A Systematic Review. Biomed Res Int 2018; 2018:1250721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter J, Katz E, Scammell TE, Maski K. Usefulness of a Nocturnal SOREMP for Diagnosing Narcolepsy with Cataplexy in a Pediatric Population. Sleep 2015; 38:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bin-Hasan S, Videnovic A, Maski K. Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy. J Clin Sleep Med 2018; 14:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen JA, Carrillo O, Leary EB, et al. Sleep-stage transitions during polysomnographic recordings as diagnostic features of type 1 narcolepsy. Sleep Med 2015; 16:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvani A, Vandi S, Pizza F, et al. Combining information on nocturnal rapid eye movement sleep latency and atonia to facilitate diagnosis of pediatric narcolepsy type 1. Sleep 2021; 44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris SF, Monderer RS, Thorpy M. Hypersomnias of central origin. Neurol Clin 2012; 30:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotagal S, Nichols CD, Grigg-Damberger MM, et al. Non-respiratory indications for polysomnography and related procedures in children: an evidence-based review. Sleep 2012; 35:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krahn LE, Arand DL, Avidan AY, et al. Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine. J Clin Sleep Med 2021; 17:2489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended Amount of Sleep for Pediatric Populations: A Consensus Statement of the American Academy of Sleep Medicine. J Clin Sleep Med 2016; 12:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansukhani MP, Dhankikar S, Kotagal S, Kolla BP. The influence of antidepressants and actigraphy-derived sleep characteristics on pediatric multiple sleep latency testing. J Clin Sleep Med 2021; 17:2179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz ES, Maski K, Jenkins AJ. Drug testing in children with excessive daytime sleepiness during multiple sleep latency testing. J Clin Sleep Med 2014; 10:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann-Vogel H, Hoff S, Valko PO, et al. Extending sleep to confirm insufficient sleep syndrome is challenging. J Sleep Res 2021; 30:e13109.
          </a>
         </li>
         <li class="breakAll">
          Carskadon MA. The second decade. In: Sleeping and Waking Disorders: Indications and Techniques, Guilleminault C (Ed), Addison Wesley, 1982. p.99.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizza F, Barateau L, Jaussent I, et al. Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1. Neurology 2019; 93:e1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008; 7:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001; 50:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krahn LE, Pankratz VS, Oliver L, et al. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002; 25:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20:1012.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 97853 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23246544" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17310860" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The epidemiology of narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24006291" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Increase of histaminergic tuberomammillary neurons in narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10615891" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hypocretin (orexin) deficiency in human narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11055430" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Reduced number of hypocretin neurons in human narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30546103" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The neurobiological basis of narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32933368" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Secondary Narcolepsy in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7701195" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Symptomatic narcolepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29909138" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22569157" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008665" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33567377" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sleep disorders in Prader-Willi syndrome, evidence from animal models and humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8628463" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cataplexy and monoamine oxidase deficiency in Norrie disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12749547" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12841368" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7137965" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cataplexy in variant forms of Niemann-Pick disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11336895" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36595587" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Changed epidemiology of narcolepsy before, during, and after the 2009 H1N1 pandemic: a nationwide narcolepsy surveillance network study in mainland China, 1990-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35695235" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Increased incidence of pediatric narcolepsy following the 2009 H1N1 pandemic: a report from the pediatric working group of the sleep research network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31062443" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23486871" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25264897" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21866560" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26123389" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26022571" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The narcolepsy-pandemic influenza story: can the truth ever be unraveled?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26136476" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30541895" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26235160" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Frequencies and Associations of Narcolepsy-Related Symptoms: A Cross-Sectional Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1968069" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918805" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27923434" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Narcolepsy in children
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25838042" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Narcolepsy in children: a diagnostic and management approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26118560" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12841372" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20132530" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical utility of the Chinese version of the Pediatric Daytime Sleepiness Scale in children with obstructive sleep apnea syndrome and narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28822033" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical and polysomnographic characteristics of excessive daytime sleepiness in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28449902" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Validation of the Epworth Sleepiness Scale for Children and Adolescents using Rasch analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34920345" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Validation of the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24142146" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical and polysomnographic course of childhood narcolepsy with cataplexy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18307264" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cataplexy features in childhood narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24656461" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cataplectic facies: clinical marker in the diagnosis of childhood narcolepsy-report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32253429" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17569582" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22505856" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Characteristics of REM sleep behavior disorder in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28472332" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The spectrum of REM sleep-related episodes in children with type 1 narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015503" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26285115" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Psychosocial Characteristics of Children with Central Disorders of Hypersomnolence Versus Matched Healthy Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30476304" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Impaired social functioning in children with narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31739230" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevalence of attention deficit hyperactivity disorder symptoms in narcolepsy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30190179" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical Characteristics and Burden of Illness in Pediatric Patients with Narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25325473" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Psychiatric comorbidity and cognitive profile in children with narcolepsy with or without association to the H1N1 influenza vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15033134" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A putative link between childhood narcolepsy and obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27823707" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Body weight and basal metabolic rate in childhood narcolepsy: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11394998" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707443" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Growing Up with Type 1 Narcolepsy: Its Anthropometric and Endocrine Features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372264" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30584530" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Rapid-Onset Obesity with Hypoventilation, Hypothalamic, Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET) Syndrome: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25325489" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Usefulness of a Nocturnal SOREMP for Diagnosing Narcolepsy with Cataplexy in a Pediatric Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29351827" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26299470" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Sleep-stage transitions during polysomnographic recordings as diagnostic features of type 1 narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33035342" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Combining information on nocturnal rapid eye movement sleep latency and atonia to facilitate diagnosis of pediatric narcolepsy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23099128" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hypersomnias of central origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23115394" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Non-respiratory indications for polysomnography and related procedures in children: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34423768" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27250809" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recommended Amount of Sleep for Pediatric Populations: A Consensus Statement of the American Academy of Sleep Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34013880" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The influence of antidepressants and actigraphy-derived sleep characteristics on pediatric multiple sleep latency testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3809866" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25126037" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Drug testing in children with excessive daytime sleepiness during multiple sleep latency testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32557957" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Extending sleep to confirm insufficient sleep syndrome is challenging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32557957" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Extending sleep to confirm insufficient sleep syndrome is challenging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31405906" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565458" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : CSF hypocretin-1 assessment in sleep and neurological disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11558795" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12405608" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9456467" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
